본문 바로가기
KERD
논문KCI 등재

Cancer-Associated Stroke: Thrombosis Mechanism, Diagnosis, Outcome, and Therapeutic Strategies

유준상|김영대|남효석|Kwang Hyun Kim|Jaeseob Yun|Jae Wook Jung|Ji Hoe Heo
대한뇌졸중학회 (The Korean Stroke Society)|2024.05|대한뇌졸중영문학회지 (Journal of stroke)|제26권 제2호|pp. 164-178

3

조회

0

다운로드

1

인용

0

참고문헌

키워드

CancerStrokeThrombosisAntithrombotic agents
주제분류신경과학

초록

Cancer can induce hypercoagulability, which may lead to stroke. This occurs when tumor cells activate platelets as part of their growth and metastasis. Tumor cells activate platelets by generating thrombin and expressing tissue factor, resulting in tumor cell-induced platelet aggregation. Histopathological studies of thrombi obtained during endovascular thrombectomy in patients with acute stroke and active cancer have shown a high proportion of platelets and thrombin. This underscores the crucial roles of platelets and thrombin in cancer-associated thrombosis. Cancerassociated stroke typically occurs in patients with active cancer and is characterized by distinctive features. These features include multiple infarctions across multiple vascular territories, markedly elevated blood D-dimer levels, and metastasis. The presence of cardiac vegetations on echocardiography is a robust indicator of cancer-associated stroke. Suspicion of cancer-associated stroke during endovascular thrombectomy arises when white thrombi are detected, particularly in patients with active cancer. Cancer-associated stroke is almost certain when histopathological examination of thrombi shows a very high platelet and a very low erythrocyte composition. Patients with cancerassociated stroke have high risks of mortality and recurrent stroke. However, limited data are available on the optimal treatment regimen for stroke prevention in these patients. Thrombosis mechanism in cancer is well understood, and distinct therapeutic targets involving thrombin and platelets have been identified. Therefore, direct thrombin inhibitors and/or antiplatelet agents may effectively prevent stroke recurrence. Additionally, this strategy has potential benefits in cancer treatment as accumulating evidence suggests that aspirin use reduces cancer progression, metastasis, and cancer-related mortality. However, clinical trials are necessary to assess the efficacy of this strategy involving the use of direct thrombin inhibitors and/or antiplatelet therapies.

Abstract

Cancer can induce hypercoagulability, which may lead to stroke. This occurs when tumor cells activate platelets as part of their growth and metastasis. Tumor cells activate platelets by generating thrombin and expressing tissue factor, resulting in tumor cell-induced platelet aggregation. Histopathological studies of thrombi obtained during endovascular thrombectomy in patients with acute stroke and active cancer have shown a high proportion of platelets and thrombin. This underscores the crucial roles of platelets and thrombin in cancer-associated thrombosis. Cancerassociated stroke typically occurs in patients with active cancer and is characterized by distinctive features. These features include multiple infarctions across multiple vascular territories, markedly elevated blood D-dimer levels, and metastasis. The presence of cardiac vegetations on echocardiography is a robust indicator of cancer-associated stroke. Suspicion of cancer-associated stroke during endovascular thrombectomy arises when white thrombi are detected, particularly in patients with active cancer. Cancer-associated stroke is almost certain when histopathological examination of thrombi shows a very high platelet and a very low erythrocyte composition. Patients with cancerassociated stroke have high risks of mortality and recurrent stroke. However, limited data are available on the optimal treatment regimen for stroke prevention in these patients. Thrombosis mechanism in cancer is well understood, and distinct therapeutic targets involving thrombin and platelets have been identified. Therefore, direct thrombin inhibitors and/or antiplatelet agents may effectively prevent stroke recurrence. Additionally, this strategy has potential benefits in cancer treatment as accumulating evidence suggests that aspirin use reduces cancer progression, metastasis, and cancer-related mortality. However, clinical trials are necessary to assess the efficacy of this strategy involving the use of direct thrombin inhibitors and/or antiplatelet therapies.

참고문헌 (98)

  1. White MC, "Age and cancer risk : a potentially modifiable relationship", Am J Prev Med, 46(3 Suppl 1), pp.S7~S15 (2014)
  2. Kang MJ, "Cancer statistics in Korea : incidence, mortality, survival, and prevalence in 2020", Cancer Res Treat, 55, pp.385~399 (2023)
  3. Feigin VL, "Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016", N Engl J Med, 379, pp.2429~2437 (2018)
  4. Sanossian N, "Trends in cancer diagnoses among inpatients hospitalized with stroke", J Stroke Cerebrovasc Dis, 22, pp.1146~1150 (2013)
  5. Jang HS, "The long-term effect of cancer on incident stroke : a nationwide population-based cohort study in Korea", Front Neurol, 10, pp.52~ (2019)
  6. Navi BB, "Ischemic stroke in cancer patients : a review of an underappreciated pathology", Ann Neurol, 83, pp.873~883 (2018)
  7. Bang OY, "Cancer-related stroke : an emerging subtype of ischemic stroke with unique pathomechanisms", J Stroke, 22, pp.1~10 (2020)
  8. Dardiotis E, "Cancer-associated stroke : pathophysiology, detection and management(review)", Int J Oncol, 54, pp.779~796 (2019)
  9. Kleindorfer DO, "2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline from the American Heart Association", American Stroke Association, 2021, pp.52, e364~e467
  10. Woock M, "Cancer and stroke : commonly encountered by clinicians, but little evidence to guide clinical approach", Ther Adv Neurol Disord, 15, pp.17562864221106362~ (2022)
  11. Gay LJ, "Contribution of platelets to tumour metastasis", Nat Rev Cancer, 11, pp.123~134 (2011)
  12. Goubran HA, "The platelet-cancer loop", Eur J Intern Med, 24, pp.393~400 (2013)
  13. Mege D, "Involvement of platelets in cancers", Semin Thromb Hemost, 45, pp.569~575 (2019)
  14. Plantureux L, "Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis", Cancers(Basel), 10, pp.441~ (2018)
  15. Plantureux L, "Effects of platelets on cancer progression", Thromb Res, 164(Suppl 1), pp.S40~S47 (2018)
  16. Mezouar S, "Role of platelets in cancer and cancerassociated thrombosis : experimental and clinical evidences", Thromb Res, 139, pp.65~76 (2016)
  17. Connolly GC, "Platelets and cancer-associated thrombosis", Semin Oncol, 41, pp.302~310 (2014)
  18. Ma L, "Proteinase-activated receptors 1 and 4 counterregulate endostatin and VEGF release from human platelets", Proc Natl Acad Sci U S A, 102, pp.216~220 (2005)
  19. Haemmerle M, "The platelet lifeline to cancer : challenges and opportunities", Cancer Cell, 33, pp.965~983 (2018)
  20. Kwon MJ, "Matrix metalloproteinases as therapeutic targets in breast cancer", Front Oncol, 12, pp.1108695~ (2023)
  21. Strasenburg W, "Tumor cell-induced platelet aggregation as an emerging therapeutic target for cancer therapy", Front Oncol, 12, pp.909767~ (2022)
  22. Egan K, "Living in shear : platelets protect cancer cells from shear induced damage", Clin Exp Metastasis, 31, pp.697~704 (2014)
  23. Leblanc R, "Metastasis : new functional implications of platelets and megakaryocytes", Blood, 128, pp.24~31 (2016)
  24. Weber MR, "Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream", Thromb Res, 140(Suppl 1), pp.S27~S36 (2016)
  25. Qi C, "P-selectinmediated platelet adhesion promotes tumor growth", Oncotarget, 6, pp.6584~6596 (2015)
  26. Heinmöller E, "Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines", J Cancer Res Clin Oncol, 122, pp.735~744 (1996)
  27. Hu L, "Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis", Blood, 104, pp.2746~2751 (2004)
  28. Abdalkader M, "Endovascular versus medical management of acute basilar artery occlusion : a systematic review and meta-analysis of the randomized controlled trials", J Stroke, 25, pp.81~91 (2023)
  29. Morsi RZ, "Endovascular thrombectomy for large ischemic strokes : a living systematic review and meta-analysis of randomized trials", J Stroke, 25, pp.214~222 (2023)
  30. Heo JH, "Pathophysiologic and therapeutic perspectives based on thrombus histology in stroke", J Stroke, 22, pp.64~75 (2020)
  31. Aliena-Valero A, "Clot composition analysis as a diagnostic tool to gain insight into ischemic stroke etiology : a systematic review", J Stroke, 23, pp.327~342 (2021)
  32. Park H, "Histological features of intracranial thrombi in stroke patients with cancer", Ann Neurol, 86, pp.143~149 (2019)
  33. Fu CH, "Fibrin and platelet-rich composition in retrieved thrombi hallmarks stroke with active cancer", Stroke, 51, pp.3723~3727 (2020)
  34. Yoo J, "Coagulation factor expression and composition of arterial thrombi in cancer-associated stroke", Stroke, 54, pp.2981~2989 (2023)
  35. Ikeda H, "Factors related to white thrombi in acute ischemic stroke in cancer patients", Neuroradiol J, 36, pp.453~459 (2023)
  36. Sun YE, "Different thrombus histology in a cancer patient with deep vein thrombosis and recurrent strokes", J Stroke, 24, pp.300~302 (2022)
  37. Heo J, "Automated composition analysis of thrombus from endovascular treatment in acute ischemic stroke using computer vision", J Stroke, 24, pp.433~435 (2022)
  38. Heo J, "Cancer prediction with machine learning of thrombi from thrombectomy in stroke : multicenter development and validation", Stroke, 54, pp.2105~2113 (2023)
  39. Lee AY, "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", N Engl J Med, 349, pp.146~153 (2003)
  40. Johnson ED, "The D-dimer assay", Am J Hematol, 94, pp.833~839 (2019)
  41. Weitz JI, "A test in context : D-dimer", J Am Coll Cardiol, 70, pp.2411~2420 (2017)
  42. Naito H, "Antithrombotic therapy strategy for cancer-associated ischemic stroke : a case series of 26 patients", J Stroke Cerebrovasc Dis, 27, pp.e206~e211 (2018)
  43. Nam KW, "Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant", J Stroke Cerebrovasc Dis, 26, pp.2976~2980 (2017)
  44. Jang H, "Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke", J Oncol, 2015, pp.502089~ (2015)
  45. Yoo J, "Outcome of stroke patients with cancer and nonbacterial thrombotic endocarditis", J Stroke, 22, pp.245~253 (2020)
  46. Asopa S, "Non-bacterial thrombotic endocarditis", Eur J Cardiothorac Surg, 32, pp.696~701 (2007)
  47. Liu J, "Nonbacterial thrombotic endocarditis : pathogenesis, diagnosis, and management", Cardiol Rev, 24, pp.244~247 (2016)
  48. Itzhaki Ben Zadok O, "Cancer-associated non-bacterial thrombotic endocarditis", Thromb Res, 213(Suppl 1), pp.S127~S132 (2022)
  49. Deppisch LM, "Non-bacterial thrombotic endocarditis : clinicopathologic correlations", Am Heart J, 92, pp.723~729 (1976)
  50. Navi BB, "Recurrent thromboembolic events after ischemic stroke in patients with cancer", Neurology, 83, pp.26~33 (2014)
  51. Lee MJ, "Hypercoagulability and mortality of patients with stroke and active cancer : the OASIS-cancer study", J Stroke, 19, pp.77~87 (2017)
  52. Nam KW, "Predictors of 30-day mortality and the risk of recurrent systemic thromboembolism in cancer patients suffering acute ischemic stroke", PLoS One, 12, pp.e0172793~ (2017)
  53. Yoo J, "Short-term outcome of ischemic stroke patients with systemic malignancy", Stroke, 50, pp.507~511 (2019)
  54. Fujinami J, "Cancer-associated hypercoagulation increases the risk of early recurrent stroke in patients with active cancer", Cerebrovasc Dis, 46, pp.46~51 (2018)
  55. Nakajima S, "Post-treatment plasma D-dimer levels are associated with short-term outcomes in patients with cancerassociated stroke", Front Neurol, 13, pp.868137~ (2022)
  56. Verschoof MA, "Clinical outcome after endovascular treatment in patients with active cancer and ischemic stroke : a MR CLEAN registry substudy", Neurology, 98, pp.e993~e1001 (2022)
  57. Aboul-Nour H, "Mechanical thrombectomy for acute ischemic stroke in metastatic cancer patients : a nationwide crosssectional analysis", J Stroke, 25, pp.119~125 (2023)
  58. Yoo J, "Immediate and long-term outcomes of reperfusion therapy in patients with cancer", Stroke, 52, pp.2026~2034 (2021)
  59. Navi BB, "Ischemic stroke with cancer : hematologic and embolic biomarkers and clinical outcomes", J Thromb Haemost, 20, pp.2046~2057 (2022)
  60. Thun MJ, "Aspirin use and reduced risk of fatal colon cancer", N Engl J Med, 325, pp.1593~1596 (1991)
  61. Giovannucci E, "Aspirin use and the risk for colorectal cancer and adenoma in male health professionals", Ann Intern Med, 121, pp.241~246 (1994)
  62. Giovannucci E, "Aspirin and the risk of colorectal cancer in women", N Engl J Med, 333, pp.609~614 (1995)
  63. Smalley W, "Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer : a population-based study", Arch Intern Med, 159, pp.161~166 (1999)
  64. Baron JA, "A randomized trial of aspirin to prevent colorectal adenomas", N Engl J Med, 348, pp.891~899 (2003)
  65. Sandler RS, "A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer", N Engl J Med, 348, pp.883~890 (2003)
  66. Flossmann E, "Effect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies", Lancet, 369, pp.1603~1613 (2007)
  67. Algra AM, "Effects of regular aspirin on longterm cancer incidence and metastasis : a systematic comparison of evidence from observational studies versus randomised trials", Lancet Oncol, 13, pp.518~527 (2012)
  68. Simon TG, "Association of aspirin with hepatocellular carcinoma and liver-related mortality", N Engl J Med, 382, pp.1018~1028 (2020)
  69. Elwood PC, "Aspirin and cancer survival : a systematic review and meta-analyses of 118 observational studies of aspirin and 18cancers", Ecancermedicalscience, 15, pp.1258~ (2021)
  70. Ma S, "Does aspirin reduce the incidence, recurrence, and mortality of hepatocellular carcinoma? A GRADE-assessed systematic review and dose-response meta-analysis", Eur J Clin Pharmacol, 79, pp.39~61 (2023)
  71. Wang L, "Aspirin use and common cancer risk : a meta-analysis of cohort studies and randomized controlled trials", Front Oncol, 11, pp.690219~ (2021)
  72. Zeng RW, "Meta-analysis : chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin", Aliment Pharmacol Ther, 57, pp.600~609 (2023)
  73. Mädge JC, "Metaanalysis of aspirin-guided therapy of colorectal cancer", J Cancer Res Clin Oncol, 148, pp.1407~1417 (2022)
  74. Wiviott SD, "Prasugrel versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 357, pp.2001~2015 (2007)
  75. Hicks BM, "Clopidogrel use and cancer-specific mortality : a population-based cohort study of colorectal, breast and prostate cancer patients", Pharmacoepidemiol Drug Saf, 24, pp.830~840 (2015)
  76. Kuan YC, "Effects of aspirin or clopidogrel on colorectal cancer chemoprevention in patients with type 2 diabetes mellitus", Cancers(Basel), 11, pp.1468~ (2019)
  77. Rodríguez-Miguel A, "Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer", Clin Gastroenterol Hepatol, 17, pp.2024~2033 (2019)
  78. Cho MS, "Role of ADP receptors on platelets in the growth of ovarian cancer", Blood, 130, pp.1235~1242 (2017)
  79. Gebremeskel S, "The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer", Int J Cancer, 136, pp.234~240 (2015)
  80. Mezouar S, "Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo", Int J Cancer, 136, pp.462~475 (2015)
  81. Hua H, "Complex roles of the old drug aspirin in cancer chemoprevention and therapy", Med Res Rev, 39, pp.114~145 (2019)
  82. Mitrugno A, "Carpe low-dose aspirin : the new anti-cancer face of an old anti-platelet drug", Platelets, 29, pp.773~778 (2018)
  83. Kawano H, "Subcutaneous heparin therapy for patients with cancerassociated stroke", J Stroke Cerebrovasc Dis, 28, pp.399~404 (2019)
  84. Yamaura G, "Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism", Thromb Res, 206, pp.99~103 (2021)
  85. Navi BB, "Enoxaparin vs aspirin in patients with cancer and ischemic stroke : the teach pilot randomized clinical trial", JAMA Neurol, 75, pp.379~381 (2018)
  86. Chung JW, "Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer : a randomized clinical trial of biomarker targets", Int J Stroke (2024)[DOI]
  87. Martinez-Majander N, "Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer : a subgroup analysis of the NAVIGATE ESUS randomized trial", Eur J Neurol, 27, pp.841~848 (2020)
  88. Conen D, "Risk of malignant cancer among women with new-onset atrial fibrillation", JAMA Cardiol, 14, pp.389~396 (2016)
  89. Menichelli D, "Cancer and atrial fibrillation : epidemiology, mechanisms, and anticoagulation treatment", Prog Cardiovasc Dis, 66, pp.28~36 (2021)
  90. Hung YP, "Risk and predictors of subsequent cancers of patients with newlydiagnosed atrial fibrillation-a nationwide population-based study", Int J Cardiol, 296, pp.81~86 (2019)
  91. Atterman A, "Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer", J Intern Med, 288, pp.457~468 (2020)
  92. Kim K, "Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer", Korean Circ J, 48, pp.406~417 (2018)
  93. Shah S, "Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation", Blood Adv, 2, pp.200~209 (2018)
  94. Yang P, "Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis", Heart Fail Rev, 25, pp.823~831 (2020)
  95. Chen Y, "Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer : a meta-analysis of randomized clinical trials and observational studies", Eur J Clin Pharmacol, 77, pp.849~857 (2021)
  96. Chan YH, "Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants : a nationwide cohort study", Stroke, 52, pp.3132~3141 (2021)
  97. Deitelzweig S, "Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer", JACC CardioOncol, 3, pp.411~424 (2021)
  98. Garg A, "In-hospital outcomes and recurrence of acute ischemic stroke in patients with solid organ malignancy", Neurology, 99, pp.e393~e401 (2022)

관련 논문AI추천

Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique PathomechanismsGyeong-Moon Kim, Jong-Won Chung, Mi Ji Lee, Myung-Ju Ahn, OASIS-Cancer Study Investigators, Oh Young Bang, Woo-Keun Seo대한뇌졸중학회 · 대한뇌졸중영문학회지2020 · 제22권 제1호Ischemic Stroke and Cancer: Stroke Severely Impacts Cancer Patients, While Cancer Increases the Number of Strokes이준, 김경문, 김선경, 김한영, 박광열, 방오영, 석진명, 이광호, 정진상, 정필욱, 홍지만대한신경과학회 · Journal of Clinical Neurology2011 · 제7권 제2호Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study김경문, 김선우, 방오영, 석진명, 안명주, 이광호, 이미지, 장혜민, 정종원, 정진상대한뇌졸중학회 · 대한뇌졸중영문학회지2017 · 제19권 제1호Outcome of Stroke Patients with Cancer and Nonbacterial Thrombotic Endocarditis이혜선, Hyo Suk Nam, Hyung Jong Park, Ji Hoe Heo, Jin Kyo Choi, Joonsang Yoo, Young Dae Kim대한뇌졸중학회 · 대한뇌졸중영문학회지2020 · 제22권 제2호종양에 의한 색전과 동반된 혈전에 의한 뇌경색김효재, 박관영, 오승택, 유혜리, 장준영, 정희재대한신경과학회 · 대한신경과학회지2021 · 제39권 제4호Concurrent Use of Contact Aspiration and a Stent Retriever Is Associated With Successful Recanalization in Patients With Cancer-Associated StrokeBum Joon Kim, Deok Hee Lee, Dong-Wha Kang, Dongwhane Lee, Hyuk Sung Kwon, Jae Young Park, Jong S. Kim, Sang Hee Ha, Soo Jeong, Sun U. Kwon대한신경과학회 · Journal of Clinical Neurology2026 · 제22권 제1호

이 간행물의 다른 논문 (20건)

Leukoaraiosis: Epidemiology, Imaging, Risk Factors, and Management of Age-Related Cerebral White Matter HyperintensitiesQing Lin, Chi-Meng Tzeng, Wen-Qing Huangpp. 131-163Prevalence of Cerebral Amyloid Angiopathy Pathology and Strictly Lobar Microbleeds in East-Asian Versus Western Populations: A Systematic Review and Meta-AnalysisCatharina J.M. Klijn, Floris H.B.M. Schreuder, Marcel M. Verbeek, Anna M. De Kort, Lieke Jäkelpp. 179-189Distal Medium Vessel Occlusion Strokes: Understanding the Present and Paving the Way for a Better FutureNirav R. Bhatt, Jin Soo Lee, Mohamed F. Doheim, Raul G. Nogueira, Alhamza R. Al-Bayati, Diogo C. Haussen, Mahmoud Mohammaden, Michael Lang, Matthew Starr, Marcelo Rocha, Catarina Perry da Câmara, Bradley A. Grosspp. 190-202Neuroprotective Approaches for Brain Injury After Cardiac Arrest: Current Trends and Prospective AvenuesXiaofeng Jia, Subash Marasinipp. 203-230The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet Therapy in Preventing Stroke RecurrenceZixiao Li, Xia Meng, Anxin Wang, Qin Xu, Xuewei Xie, Jinxi Lin, Xingquan Zhao, Yong Jiang, Yilong Wang, Liping Liu, Yongjun Wang, Hao Li, Jing Jingpp. 231-241
원문 보기